Martin MacLean is a leading authority on patent law in the United Kingdom, recognised as a Patent lawyer in United Kingdom with a deep technical background in biotechnology and an outstanding track record in European patent prosecution and portfolio strategy. As a partner in the life sciences team at Mathys & Squire LLP, he is routinely instructed by multinational corporates, government bodies and sophisticated start-ups to manage complex, high-value patent portfolios across Europe and beyond. His standing in market directories and client feedback reflects sustained excellence in advisory and contentious patent work.
Martin holds a first-class undergraduate degree in microbial technology and a PhD in microbial engineering from the University of Warwick, complemented by a postgraduate master’s degree in Intellectual Property from the University of London. He trained and qualified as a patent attorney and has over two decades of specialist IP experience focused on life sciences and related technologies. Martin also serves as a tutor for the UK and European qualifying examinations for patent attorneys, and he participates in professional committees that shape life sciences practice in the UK.
Throughout his career, Martin has progressed to senior leadership within Mathys & Squire, advising on major portfolio restructuring, freedom-to-operate assessments and technical due diligence for transactions exceeding £100m in value. Clients and peers frequently commend his combination of scientific insight and commercial judgement, which underpins his role as a trusted strategic adviser.
Martin specialises in patent drafting, global prosecution, opposition and appeal work before the European Patent Office, strategic freedom-to-operate analysis, and portfolio management for life sciences businesses. His technical specialisms include protein therapeutics, antibodies, vaccines, expression systems, diagnostic assays and environmentally focused agrochemicals, giving him cross-sector experience in biotech, pharmaceuticals, agri-tech and food & beverage innovation. His practice combines frontline EPO advocacy with high-level commercial advisory work for research‑intensive clients.
Notably, Martin has conducted well in excess of 100 EPO hearings, with a demonstrated success rate underscoring his courtroom and appeal-stage capabilities. This depth of opposition and appeal experience means he is regularly instructed where the stakes are high: validity challenges, instruction-sensitive freedom-to-operate opinions and litigation-support work for commercial transactions. His pragmatic, commercially minded approach helps clients prioritise protection that aligns with business objectives rather than pursuing maximalist claim scopes.
Martin’s involvement in numerous EPO Boards of Appeal matters and regular representation before the EPO attest to his litigation-adjacent strengths. He is regularly cited in leading IP directories for landmark work and sustained client service in life sciences patenting. These recognitions reflect both individual case outcomes and longer-term portfolio management achievements for clients operating across Europe and internationally.
Martin co‑authored a chapter addressing intellectual property challenges for bacteriophages in a 2020 Springer volume, demonstrating engagement with cutting-edge biological therapeutics and the patentability nuances they present. He is also a presenter and contributor to firm-led webinars and practitioner-focused events, including sessions on patent drafting strategies tailored to European prosecution practice. These activities underline his role as a practitioner-scholar who translates complex science into patent strategies that work in practice.
Martin is consistently ranked in top-tier legal directories: Chambers & Partners Band 1, IAM’s Strategy 300 and regular recommendations in IAM Patent 1000 and The Legal 500. Client testimonials and peer commentary emphasise his technical depth, accessibility and results-driven style, especially in matters before the EPO and in global portfolio planning. These independent endorsements reinforce his market reputation as a Patent lawyer in United Kingdom life sciences practice.
The United Kingdom patent landscape remains technically rigorous and commercially consequential for life sciences innovators: securing and enforcing patent rights requires precise drafting, strategic territorial coverage and an appreciation of evolving EPO and national case law. Key challenges for clients include navigating examination practice at the EPO, managing oppositions and appeals, aligning patent strategy with regulatory exclusivities such as SPCs, and mitigating freedom-to-operate risks in multi-jurisdictional markets.
Specialist expertise matters because the intersection of advanced biology and patent law demands both scientific literacy and procedural mastery. Advisers who combine deep technical knowledge with appellate experience are better placed to draft robust claims, defend them effectively before patent offices and design global filing strategies that maximise commercial value while minimising litigation exposure. Martin’s blend of bench-level biotech experience and appeal-room track record addresses these precise client needs.
Businesses and individuals seeking a Patent lawyer in United Kingdom should consider Martin if they require counsel on high‑value biotech and pharmaceutical portfolios, complex prosecution before the EPO, opposition and appeal strategy, or transaction-related IP due diligence. He is particularly well suited to life sciences companies developing therapeutic proteins, vaccines, diagnostics or biologically derived agrochemicals where technical subtleties determine patent scope and commercial freedom.
Martin’s clients include early-stage innovators needing sound drafting to preserve global options, multinational R&D organisations seeking streamlined portfolio management, and acquiring parties requiring technically rigorous diligence on biological assets. In each engagement his emphasis is on practical, commercially aligned outcomes that support growth, licensing and enforcement objectives.
Martin MacLean combines an exceptional scientific background with proven advocacy and strategic portfolio management skills, making him a leading Patent lawyer in United Kingdom life sciences practice. His top-tier directory rankings, EPO advocacy record and specialist publications evidence a practitioner capable of navigating the most technically demanding patent matters. For clients whose IP is a core commercial asset, Martin offers the technical rigour and procedural experience needed to secure and defend valuable patent rights across Europe and beyond.
Find the right Legal Expert for your business
Sign up for the latest advisor briefings and news within Global Advisory Experts’ community, as well as a whole host of features, editorial and conference updates direct to your email inbox.
Naturally you can unsubscribe at any time.
Global Advisory Experts is dedicated to providing exceptional advisory services to clients around the world. With a vast network of highly skilled and experienced advisors, we are committed to delivering innovative and tailored solutions to meet the diverse needs of our clients in various jurisdictions.
